Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome

Milani, Rodolfo; Scalambrino, S.; Milia, R.; Sambruni, I.; Riva, Diego Della; Pulici, Luca; Avaldi, F.; Viganò, Riccardo

doi:10.1007/bf00372799

Cited by 29 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study confirms that bladder volume at first urge tends to increase, in this instance by an average of 60 ml (30%), an effect that tended to favor patients suffering from sensory urge incontinence. This increase is comparable to the results of other investigations with flavoxate [8,10,13]. Milani et al [8] found an addition increase of 80 ml with a higher dosage of 1200 mg flavoxate.…”

Section: Discussionsupporting

confidence: 81%

“…This increase is comparable to the results of other investigations with flavoxate [8,10,13]. Milani et al [8] found an addition increase of 80 ml with a higher dosage of 1200 mg flavoxate.…”

Section: Discussionsupporting

confidence: 81%

“…Research has shown that flavoxate improves intravesical pressure and increases bladder capacity by up to 19% [10,12]. At the same time, accompanying symptoms which are annoying for patients, such as increased daytime and nighttime frequency as well as urge micturition, were found to decrease [8,11]. This study confirms that bladder volume at first urge tends to increase, in this instance by an average of 60 ml (30%), an effect that tended to favor patients suffering from sensory urge incontinence.…”

Section: Discussionmentioning

confidence: 93%

“…A number of authors prefer flavoxate anticholinergics for the treatment of urge incontinence in view of its better benefit-risk ratio [8]; moreover, there is some evidence for therapeutic success in patients initially treated unsuccessfully with anticholinergics [9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Using Flavoxate as Primary Medication for Patients Suffering from Urge Symptomatology

1999

View full text Add to dashboard Cite

A drug utilization observation study collected data on a total of 1800 patients given flavoxate (Spasuret 200) over 2 weeks for urge incontinence. Efficacy and tolerance parameters were determined. A subgroup of 618 patients without urinary tract infections or benign prostatic hyperplasia were treated with flavoxate only. The subgroup (n = 618) showed a reduction of dysuria (37%), nocturia (53%), and both daytime (61%) and nighttime urge (69%). Bladder volume at first urge sensation increased by 55.1+/-58.8 ml (36%), which was comparable to data from the entire group (1800 patients). In 89.2% of all patients the residual urine volume was stable or decreased. Undesirable side effects occurred in 1.8% of cases. Both groups showed better results with flavoxate four times daily (800 mg), compared to three times daily (600 mg). Flavoxate is effective and well tolerated and causes no additional problems due to residual urine or side effects.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Using Flavoxate as Primary Medication for Patients Suffering from Urge Symptomatology

1999

View full text Add to dashboard Cite

show abstract

“…[17]. Milani et al [18] showed no difference in efficacy between flavoxate 1,200 mg/day and oxybutynin 15 mg daily in 41 women with idiopathic motor or sensory urgency, with flavoxate showing fewer and milder side effects.…”

Section: Flavoxate Hydrochloridementioning

confidence: 99%

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

Asimakopoulos

Cerruto²,

Popolo³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Objectives: To provide an overview on the efficacy, tolerability, safety and health-related quality of life (HRQoL) of drugs with a mixed action used in the treatment of overactive bladder (OAB). Evidence Acquisition: MEDLINE database and abstract books of the major conferences were searched for relevant publications from 1966 to 2011 and using the key words ‘overactive bladder’, ‘detrusor overactivity’, ‘oxybutynin’, ‘propiverine’, and ‘flavoxate’. Two independent reviewers considered publications for inclusion and extracted relevant data, without performing a meta-analysis. Evidence Synthesis: Old and conflicting data do not support the use of flavoxate, while both propiverine and oxybutynin were found to be more effective than placebo in the treatment of OAB. Propiverine was at least as effective as oxybutynin but with a better tolerability profile even in the pediatric setting. Overall, no serious adverse event for any product was statistically significant compared to placebo. Improvements were seen in HRQoL with treatment by the oxybutynin transdermal delivery system and propiverine extended release. Conclusions: While there is no evidence to suggest the use of flavoxate in the treatment of OAB, both oxybutynin and propiverine appear efficacious and safe. Propiverine shows a better tolerability profile than oxybutynin. Both drugs improve HRQoL of patients affected by OAB. Profiles of each drug and dosage differ and should be considered in making treatment choices.

show abstract

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

Roxburgh

Cook

Dublin

2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Many of the drugs considered in trials in this review are no longer used in clinical practice (and this includes the most commonly tested - flavoxate). There is inadequate no evidence as to whether any of the available is better or worse than anticholinergic medications. Larger randomised controlled trials in clinical settings are required to further establish the role of these other medications in the management of overactive bladder syndrome.

show abstract

Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome

Cited by 29 publications

References 9 publications

Using Flavoxate as Primary Medication for Patients Suffering from Urge Symptomatology

Using Flavoxate as Primary Medication for Patients Suffering from Urge Symptomatology

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

Contact Info

Product

Resources

About